Heidelberg University Hospital
Heidelberg, 69120, Germany
Location status: Recruiting
NCT Number: NCT07420374
ARTIFICE is a prospective, multicenter, randomized, controlled, exploratory non-inferiority trial evaluating whether an ambulatory stroke unit model (aSU) is non-inferior to conventional inpatient stroke unit care (SU) in patients aged 60 years or older with acute ischemic stroke, transient ischemic attack (TIA), or retinal ischemia and non-disabling neurological deficits.
Eligible patients are randomized 1:1 to same-day comprehensive ambulatory multiprofessional stroke evaluation (aSU) or guideline-based inpatient stroke unit treatment (SU). The primary endpoint is favorable functional outcome at 90 days, defined as modified Rankin Scale (mRS) 0-2 or return to pre-stroke mRS. Endpoint assessment at 90 days is performed by blinded assessors (PROBE design).
Secondary outcomes include early neurological deterioration, recurrent stroke, delirium, mortality, health-related quality of life, healthcare utilization, and cost-effectiveness. A mixed-methods process evaluation examines feasibility, acceptability, and implementation aspects of the ambulatory care model.
Interested in participating?
Request Info60 year and older
All sexes
Interventional
Not applicable
Heidelberg, 69120, Germany
Location status: Recruiting
Stroke unit treatment in Germany is currently organized as multi-day inpatient care regardless of stroke severity. However, a substantial proportion of patients with acute ischemic stroke or transient ischemic attack present with non-disabling or fully regressed neurological deficits and may not require prolonged inpatient monitoring. At the same time, demographic changes and increasing stroke incidence in older populations challenge inpatient stroke unit capacity and resource allocation.
International experience with structured outpatient TIA and minor stroke clinics suggests that ambulatory management models may provide comparable clinical safety while reducing hospital utilization. However, randomized evidence for such models within the German healthcare system is lacking.
The ARTIFICE trial evaluates a structured ambulatory stroke unit care model designed to provide comprehensive same-day multiprofessional assessment and initiation of secondary prevention while maintaining patient safety. The study investigates whether this ambulatory care approach can represent a medically safe and resource-efficient alternative to conventional inpatient stroke unit treatment in selected older patients.
In addition to clinical effectiveness, the study examines patient-reported outcomes, healthcare utilization, cost-effectiveness, and implementation aspects to inform future health services planning.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Structured ambulatory stroke care model providing same-day neurological assessment, diagnostic work-up, therapeutic evaluation, and multidisciplinary case review, followed by discharge home if medically appropriate.
Standard inpatient stroke unit treatment according to national clinical guidelines, including hospital-based monitoring, diagnostic evaluation, and initiation of secondary prevention.
Time frame: 90 days (±14 days) after randomization
Favorable functional outcome defined as modified Rankin Scale (mRS) score 0-2 or return to pre-stroke mRS level, assessed by blinded outcome assessors.
Time frame: Within 7 days after randomization
Increase in National Institutes of Health Stroke Scale (NIHSS) score of ≥4 points compared to baseline.
Time frame: Up to 90 days after randomization (primary safety observation period)
Occurrence of recurrent ischemic stroke, hemorrhagic stroke, or transient ischemic attack during follow-up.
Time frame: Within 7 days after randomization
Occurrence of delirium assessed using the Confusion Assessment Method (CAM).
Time frame: 90 days and 12 months after randomization
Death from any cause.
Time frame: Baseline and 90 days
Change in Barthel Index score from baseline to 90 days.
Time frame: Baseline and 90 days
Change in SIS-16 score from baseline to 90 days.
Time frame: Baseline and 90 days
Change in Timed Up and Go Test (TUG) time from baseline to 90 days.
Time frame: Baseline and 90 days
Change in EQ-5D-5L index value and EQ visual analogue scale (EQ-VAS) from baseline to 90 days.
Time frame: Up to 90 days after randomization
Use of outpatient, inpatient, and nursing care services assessed by questionnaire.
Time frame: Up to 90 days after randomization
Occurrence of serious adverse events including unplanned hospitalization or death.
Contact information is provided by the study sponsor or research team.
University Hospital Heidelberg
Other
Ambulatory Stroke Unit Treatment for Elderly Patients: A Prospective, Randomized, Controlled, Exploratory Non-Inferiority Trial (ARTIFICE)
Acronym: ARTIFICE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07687706
Brain Diseases, Brain Ischemia
Busan, South Korea
View Trial DetailsNCT06783049
Brain Diseases, Brain Ischemia
Beijing, Beijing Municipality, China
View Trial DetailsNCT07143149
Brain Diseases, Brain Ischemia
Beijing, China
View Trial DetailsNCT02900521
Brain Diseases, Brain Hemorrhage
Brest, France
View Trial Details